All In Biotech

Drug Trial Radar · NCT07034768

A Study to Evaluate EDG-7500 in People With Renal Impairment

A Phase 1, 2-Part, Open-Label Study to Evaluate the Pharmacokinetics of a Single Oral Dose of EDG-7500 in Participants With Impaired and Normal Renal Function

Last checked: Nov 19, 2026Latest source record: Mar 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

37

Actual

Start

Jul 22, 2025

Primary completion

Dec 22, 2025

Study completion Dec 26, 2025

Sponsor

Lead sponsor
Edgewise Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jun 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Parallel
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this Phase 1 study is to understand and compare the amount of EDG-7500 in the blood after a single dose in participants with different levels of kidney function impairment versus participants with normal kidney function. The safety of EDG-7500 in participants with different levels of kidney function impairment will also be evaluated in this study.

Conditions

  • Renal Impairments

Interventions

  • EDG-7500Drug

    Single dose of EDG-7500

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under the curve from time zero to last quantifiable concentration (AUC0-last)Time frame: Pre-dose to day 11
  2. Area under the curve from time zero to extrapolated infinite time (AUC0-inf)Time frame: Pre-dose to day 11
  3. Maximum observed plasma concentration (Cmax)Time frame: Pre-dose to day 11
  4. Observed plasma concentration at the end of the dosing interval (C24)Time frame: Pre-dose to day 11
  5. Time to reach maximum observed plasma concentration (Tmax)Time frame: Pre-dose to day 11
  6. Plasma elimination half-life (T1/2)Time frame: Pre-dose to day 11

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • The University of Miami Division of Clinical Pharmacology

    Miami, Florida

  • Orlando Clinical Research Center

    Orlando, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.